Physician profile
Rena M Jaffe
NPI 1821307257
$890.39
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $42.29 · 2023: $284 · 2024: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $219.37 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $167.64 | 2021-2023 | Mounjaro |
| Exact Sciences Corporation | $134.90 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $75.95 | 2021-2023 | |
| Pfizer INC. | $48.89 | 2023-2024 | |
| Glaxosmithkline, LLC. | $46.33 | 2021-2024 | Arexvy, Shingrix |
| Dynavax Technologies Corporation | $30.86 | 2023-2024 | Heplisav-B |
| Avanir Pharmaceuticals, INC. | $28.15 | 2021 | |
| Amarin Pharma, INC. | $27.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.90 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $15.56 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $14.96 | 2023 | Breztri |
| Merck Sharp & Dohme LLC | $13.52 | 2021 | |
| Neurelis, INC. | $13.34 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.09 | 2023 | Nuzyra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12.98 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.